Hofferth v. Janssen Pharmaceuticals, Inc.

CourtDistrict Court, D. South Carolina
DecidedMarch 5, 2020
Docket3:17-cv-01560
StatusUnknown

This text of Hofferth v. Janssen Pharmaceuticals, Inc. (Hofferth v. Janssen Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. South Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hofferth v. Janssen Pharmaceuticals, Inc., (D.S.C. 2020).

Opinion

Apes Disipe □□□ 3 □□ cc Z Cori” IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF SOUTH CAROLINA COLUMBIA DIVISION THOMAS JOSHUA HOFFERTH, § Plaintiff, § § vs. § Civil Action No.: 3:17-01560-MGL § JANSSEN PHARMACEUTICALS, INC., § JANSSEN, L.P., JOHNSON & JOHNSON, § and JANSSEN RESEARCH AND § DEVELOPMENT, LLC, § Defendants. § § MEMORANDUM OPINION AND ORDER GRANTING IN PART AND DENYING IN PART DEFENDANTS’ MOTION TO EXCLUDE EXPERT TESTIMONY AND DEEMING MOOT DEFENDANTS’ MOTION TO STRIKE

I. INTRODUCTION This is an action for various tort-based claims under South Carolina law. The Court has Jurisdiction over this matter under 28 U.S.C. § 1332. Pending before the Court are Defendants Janssen Pharmaceuticals, Inc., Janssen, L.P., Johnson & Johnson, and Janssen Research & Development, LLC’s (collectively Defendants) motions to exclude the expert testimony of L. Randolph Waid (Waid) and to strike the declaration of Waid. Having carefully considered Defendants’ motion, the response, the reply, the record, and the applicable law, it is the judgment of the Court Defendants’ motion to exclude expert testimony

of Waid will be granted in part and denied in part, and Defendants’ motion to strike will be deemed moot.

II. FACTUAL AND PROCEDURAL HISTORY

Plaintiff Thomas Joshua Hofferth (Hofferth) filed the immediate action alleging numerous South Carolina tort violations—strict products liability, negligence, failure to warn, breach of warranty of merchantability, breach of express warranty, breach of implied warranty, fraud, and negligent misrepresentation—based upon his use of two antipsychotic pharmacological drugs produced by Defendants, Risperdal and Invega. Hofferth, now twenty-eight years old, was diagnosed with possible bipolar disorder as a child, and during the course of his treatment, prescribed the two medications. During his treatment, Hofferth experienced significant weight gain, and was eventually diagnosed with gynecomastia. Gynecomastia is an enlargement or welling of breast tissue in males.

Hofferth, during discovery, limited his allegations to the contraction of gynecomastia purportedly because of his use of Risperdal and/or Invega. Pl. Fifth Supplemental Answers to Defs’ First Set of Interrog., Nos. 7-8. Hofferth’s claims were further limited when his own causation expert, Isaacs, conceded the purported side effect, gynecomastia, was caused only by Invega, not Risperdal. Exhibit 1 to Motion to Exclude Expert Testimony of Dr. Scott D. Isaacs, M.D. at 17 [hereinafter Isaacs Report] (“Thus, after eliminating any potential or contributory causes, it is, to a reasonable degree of scientific and medical certainty, Invega was the cause of Thomas Hofferth’s gynecomastia.”); see also id. at 14 (“Risperdal did not likely cause Mr. Hofferth’s chronic gynecomastia.”). Accordingly, the case before the Court is the legal implications of Invega’s purported health effects on Hofferth. Hofferth retained Waid, a South Carolina certified clinical psychologists, to provide a psychological evaluation of Hofferth in connection with the case.

After the discovery process, Defendants filed four motions to exclude the expert testimony of Martin T. Wells (Wells), Waid, Dr. David A. Kessler (Kessler), and Dr. Scott D. Isaacs (Isaacs). Hofferth responded to all four motions and Defendants replied. The Court addressed the motions pertaining to Wells, Kessler and Isaacs at a hearing held as to those three motions. The Court is now prepared to rule on the motion pertaining to Waid.

III. STANDARDS OF REVIEW Under Federal Rule of Evidence 702, a witness may be qualified as an expert to provide opinion testimony when: (a) the expert’s scientific, technical, or other specialized knowledge will help the trier of fact to understand the evidence or to determine a fact in issue; (b) the testimony is based on sufficient facts or data; (c) the testimony is the product of reliable principles and methods; and (d) the expert has reliability applied the principles and methods to the facts of the case.

Id. The rule creates a “gatekeeping requirement” for the trial court to “ensure the reliability and relevancy of expert testimony,” and to ensure “the same level of intellectual rigor that characterizes the practice of an expert in the relevant field” is presented in the courtroom. Kumho Tire Co. v. Carmichael, 526 U.S. 137, 152 (1999). The Court is required to determine whether “an expert’s testimony both rests on a reliable foundation and is relevant to the task at hand.” Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 597 (1993). The Court may rely on the Supreme Court’s set of non-exclusive factors in making determinations on the reliability of the reasoning or methodology of the experts: 1) “whether [the] theory or technique . . . can be (and has been) tested”; 2) “whether the theory or technique has been subjected to peer review and publication”; 3) “the known or potential rate or error” of a methodology and “the existence and maintenance of standards of controlling the

technique’s operation”; and 4) the general acceptance of the theory within the “relevant scientific community.” Id. at 593-94. No single factor is determinative; the “inquiry is a flexible one,” providing a trial court with “broad discretion in choosing which Daubert factors to apply and how to consider them.” Belville v. Ford Motor Co., 919 F.3d 224, 233 (4th Cir. 2019). The relevance inquiry requires analysis of whether the expert opinions have “a valid scientific connection to the pertinent inquiry. Id. at 232. Put differently, relevance requires “expert opinions to assist the trier of fact to understand the evidence or to determine a fact in issue.” United States v. Ancient Coin Collectors Guild, 899 F.3d 295, 318 (4th Cir. 2018) (internal quotations omitted). This mirrors the relevancy test in the Federal Rules of Evidence. Fed. R. Evid. 401 (“Evidence is relevant if . . . it has any tendency to make a fact more or less probable than it would

be without the evidence . . . and . . .the fact is of consequence in determining the action.”).

IV. DISCUSSION AND ANALYSIS Waid is a South Carolina certified clinical psychologist Hofferth engaged to provide a psychological evaluation of Hofferth in connection with the case. Defendants challenge the reliability of causation opinions Waid offers and the relevance of Waid’s testimony. The majority of Waid’s report lays out Hofferth’s medical history along with Hofferth’s statements to Waid during the course of Waid’s evaluation. It would be improper to certify Waid as an expert, merely for him to provide a recitation of factual testimony. A factual recitation, however, is proper if used to support independent conclusions relevant to the case. See United States v. Palacios, 677 F.3d 234, 244 (4th Cir. 2012) (allowing expert testimony to discuss factual information received from an interview when it

serves as the basis for independent opinions, rather than being used to simply pass along testimonial facts).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
United States v. Palacios
677 F.3d 234 (Fourth Circuit, 2012)
United States v. Ancient Coin Collectors Guild
899 F.3d 295 (Fourth Circuit, 2018)
Lance Belville v. Ford Motor Company
919 F.3d 224 (Fourth Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Hofferth v. Janssen Pharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/hofferth-v-janssen-pharmaceuticals-inc-scd-2020.